Highest-materiality recent filing
GT Biopharma reduces stockholder meeting quorum from majority to one-third
Board approved amendment to bylaws effective June 8, 2026.
GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price
Received Nasdaq Staff letter on May 20, 2026 granting 180-day extension until Nov 16, 2026 for minimum bid price compliance.
GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550
Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified
Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.
GT Biopharma receives Nasdaq delisting notice for low bid price
Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.
GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026
Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.
GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement
All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.
GT Biopharma series L preferred holders waive redemption rights permanently
Holders of Series L 10% Convertible Preferred Stock waived redemption rights under Section 10 of the Certificate of Designations.
GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025
CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.
GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment
All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.
GT Biopharma appoints new director, amends equity facility to raise up to $20M
Andrew Ritter resigned from board effective June 9, 2025.
GT Biopharma expands private placement to $5.95M, adds new investor Marzilli
Increased Series L preferred offering to 6,612 shares ($5.95M) from 6,056 shares ($5.45M) via First Amendment on May 21, 2025.
Private placement of up to 6,056 shares of Series L 10% Convertible Preferred Stock at $1,000 stated value; net proceeds $5.45M.
GT Biopharma appoints two new directors; two resign; board reduced to four
Board increased from 4 to 6 on May 7; Hilary Kramer appointed as non-employee director.
GT Biopharma appoints Michael Breen as CEO, effective April 29, 2025
Michael Breen appointed CEO for a two-year term; he had served as Interim CEO since March 2022.
GT Biopharma issues pre-funded warrant to Cytovance for 326,251 shares as service consideration
Issued pre-funded warrant to purchase up to 326,251 shares of common stock at $0.0001 per share.
Entered inducement letters with holders of 302,069 existing warrants to exercise at reduced price of $2.27/share, raising ~$0.7M gross proceeds.
GT Biopharma doses first patient in Phase 1 trial of GTB-3650 for hematologic malignancies
GTB-3650 is a second-generation TriKE using camelid nanobody technology to improve potency and binding affinity.
GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum
Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.
GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML
Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.
Dr. Jeffrey Miller ceased as Consulting Chief Medical Officer and Consulting Chief Scientific Officer effective September 16, 2024.
GT Biopharma receives FDA clearance for IND of GTB-3650; Phase 1 trial to start H2 2024
FDA cleared IND for GTB-3650, an NK cell engager for CD33+ leukemias; Phase 1 trial initiation expected H2 2024.
GT Biopharma annual meeting elects all four directors, ratifies auditor
Quorum: 691,084 shares (50.05%) represented at June 25 annual meeting.
GT Biopharma appoints Alan Urban as CFO after terminating Manu Ohri
Manu Ohri's employment as CFO terminated effective June 3, 2024.
GT Biopharma raises $3.2M in registered direct offering; issues warrants at $4.35 per share
Gross proceeds of ~$3.2M from sale of 740,000 shares at $4.35/share in registered direct offering.
GT Biopharma amends agreement with Cytovance to raise ownership cap from 4.9% to 9.9%
Cytovance's beneficial ownership limit raised from 4.9% to 9.9% of GT Biopharma's outstanding common stock.
GT Biopharma announces 1-for-30 reverse stock split to regain Nasdaq compliance
Reverse split ratio 1:30 effective 5:00 PM ET Feb 2, 2024; post-split trading begins Feb 5.
GT Biopharma shareholders approve reverse stock split authorization at ratio of 1:5 to 1:30
Special meeting on Dec 18, 2023; 58.13% of outstanding shares voted.
GT Biopharma submits IND to FDA for GTB-3650 for CD33+ leukemia
IND submitted for GTB-3650, a 2nd generation nanobody TriKE targeting CD33+ leukemia (relapsed/refractory AML and high-risk MDS).
GT Biopharma gets Nasdaq extension to Feb 20, 2024 for bid price compliance
Company has until Feb 20, 2024 to close at $1.00 for 10 consecutive days to regain compliance.
GT Biopharma annual meeting elects four directors, ratifies auditor
Elected directors Michael Breen, Rajesh Shrotriya, Bruce Wendel, and Charles Casamento with majority for votes.
GT Biopharma appoints Charles Casamento to board; Alan Urban resigns
Charles J. Casamento appointed to board effective May 1, 2023, to fill vacant seat.
GT Biopharma receives Nasdaq deficiency notice for bid price below $1.00 per share
Received Nasdaq deficiency letter on Feb 22, 2023; stock closed below $1.00 for 30 consecutive business days.
GT Biopharma raises $6.5M in registered direct offering of shares and warrants at $1.00 per unit
Offering of 6.5M shares or pre-funded warrants plus 6.5M warrants to purchase common stock.
GT Biopharma announces departure of President of R&D and CMO Gregory Berk
Dr. Gregory Berk no longer employed as President of R&D and Chief Medical Officer effective December 8, 2022.
GT Biopharma adopts amended bylaws with proxy access and exclusive forum provisions
Amended bylaws effective Nov 3, 2022 include proxy access for eligible long-term shareholders.
GT Biopharma shareholders vote to reduce authorized common stock from 750M to 250M shares
Special meeting held Oct 10, 2022; 17,442,945 of 31,092,498 shares represented (56.1%).
GT Biopharma adjourns special shareholders meeting due to lack of quorum; reconvened Oct 10
Special meeting on Sept 28 lacked quorum; adjourned to Oct 10, 2022 at 11 a.m. PST.
GT Biopharma settles $6.5M Cytovance debt with stock and cash; aims for IND filings by Mar/Jun 2023
Issued 1,222,281 shares to Cytovance to settle $3.25M of invoices; will pay another $3.25M in cash over three months.
GT Biopharma amends 8-K to correct vote tabulation on authorized shares reduction
Proposal 4 to reduce authorized shares from 750M to 250M passed with 19,568,632 For, 215,253 Against, 141,506 Abstain.
Elected directors Breen, Shrotriya, and Wendel with majority support (for votes 58-61% of shares present).
GT Biopharma appoints Alan L. Urban to Board and Audit Committee
Alan L. Urban appointed to fill vacant Board seat and serve on Audit Committee effective June 9, 2022.
GT Biopharma names Michael Breen Interim CEO; Gregory Berk becomes President R&D/CMO
Michael Breen named Interim CEO effective March 2, 2022; base compensation raised to $515,000.
GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO
Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.
GT Biopharma regains Nasdaq compliance for independent director and audit committee rules
Received Nasdaq Staff letter on Dec 22, 2021 confirming compliance with Listing Rule 5605(b)(1).
GT Biopharma director Anthony Cataldo resigns from board
Anthony Cataldo resigned as a member of the Board of Directors on December 15, 2021.
GT Biopharma fails Nasdaq independent director rule; cure until Nov 2022
Received Nasdaq notice on Nov 23, 2021 for non-compliance with Listing Rule 5605 after appointing Michael Breen as Executive Chairman.
GT Biopharma files 8-K to announce updated corporate presentation on website; no specifics disclosed
Filing states corporate presentation as of Nov 1, 2021 was posted to company website.
GT Biopharma files 8-K regarding ESMO 2021 presentation; no financial results disclosed
Dr. Jeffrey Miller presented on GT Biopharma's drug candidates at ESMO Congress 2021.
GT Biopharma holds business teleconference on Sep 13, 2021; presentation slide content not disclosed
Company presented business overview via teleconference on September 13, 2021.
On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.
On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.
appointed Hilary Kramer as a non-employee director to fill the vacancy created by the increase in the size of the Board
appointed Andrew Ritter as a non-employee director to fill one of the vacancies on the Board.
Bruce Wendel resigned as a member of the Board and all committees thereof.
Rajesh Shrotriya resigned as a member of the Board and all committees thereof.
On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.
Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.
In connection with Mr. Ohri’s termination, on June 3, 2024, the Company has appointed Alan L. Urban as the Company’s Chief Financial Officer.
On June 3, 2024, Manu Ohri’s employment as Chief Financial Officer at GT Biopharma, Inc. (the “Company”) was terminated.
the Registrant’s Board appointed Charles J. Casamento to fill a vacant seat on the Board
On May 1, 2023 Alan Urban resigned as a member of the Registrant’s Board of Directors (the “Board”).
Max materiality 0.90 · Median 0.50 · Most common event other_material